Retraction
Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma
Paper Information
Record ID:
58804
Author(s):
Publication Date:
April 28, 2017
Retraction Date:
September 08, 2023
(2.2 years years ago)
Subjects:
Institutions:
- Department of Medicine, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, United States of America
- Department of Research & Development, Greater Los Angeles Veterans Affairs Healthcare System, Los Angeles, California, United States of America
- Department of Chemistry and Biochemistry, University of California-Los Angeles, Los Angeles, California, United States of America
- Jonnson Comprehensive Cancer Center, University of California-Los Angeles, Los Angeles, California, United States of America
- Molecular Biology Institute, University of California-Los Angeles, Los Angeles, California, United States of America
Country:
🇺🇸 United StatesArticle Type:
Publisher:
PLoS
Open Access:
Yes
PubMed ID:
Retraction PubMed ID:
Retraction Details
Retraction Reasons:
- Concerns/Issues about Results and/or Conclusions
- Duplication of/in Image
- Error in Image
- Euphemisms for Duplication
- Investigation by Company/Institution
- Investigation by Journal/Publisher
- Misconduct - Official Investigation(s) and/or Finding(s)
- Misconduct by Author
- Original Data and/or Images not Provided and/or not Available
- Unreliable Results and/or Conclusions
- Upgrade/Update of Prior Notice(s)
Nature of Retraction:
Retraction
Retraction Notice:
10.1371/journal.pone.0291490Additional Notes:
Alan Lichtenstein has VA finding of misconduct: see https://www.federalregister.gov/documents/2024/11/18/2024-26756/findings-of-research-misconduct-c;
Citations (79)
79
Total Citations9
Post-Retraction(11.4%)
69
Pre-Retraction1
Same DayPost-Retraction Citation Analysis
1
Within 30 days
6
Within 1 year
0
After 2+ years
472
Days since retraction (latest)
Nuclear Functions of TOR: Impact on Transcription and the Epigenome
R. Nicholas Laribee, Ronit Weisman
Genes
Open Access
Published: Jun 2020
33 citations
33 citations
1185 days before retraction
The flipside of the TOR coin – TORC2 and plasma membrane homeostasis at a glance
Margot Riggi, Beata Kuśmider, Robbie Loewith
Journal of Cell Science
Open Access
Published: May 2020
42 citations
42 citations
1225 days before retraction
The 3.2Å resolution structure of human mTORC2
Alain Scaiola, Francesca Mangia, Stefan Imseng et al. (10 authors)
bioRxiv (Cold Spring Harbor Laboratory)
Open Access
Published: Apr 2020
4 citations
4 citations
1246 days before retraction
Overexpression of Rictor in the injured spinal cord promotes functional recovery in a rat model of spinal cord injury
Ningning Chen, Pengxiang Zhou, Xizhe Liu et al. (7 authors)
The FASEB Journal
Open Access
Published: Mar 2020
15 citations
15 citations
1256 days before retraction
LncRNA FOXD3-AS1 Mediates AKT Pathway to Promote Growth and Invasion in Hepatocellular Carcinoma Through Regulating RICTOR
Chao Liu, Meng Zhang, Jisen Zhao et al. (8 authors)
Cancer Biotherapy and Radiopharmaceuticals
Published: Mar 2020
13 citations
13 citations
1268 days before retraction
mTOR complex 2 is an integrator of cancer metabolism and epigenetics
Kenta Masui, Mio Harachi, Webster K. Cavenee et al. (5 authors)
Cancer Letters
Published: Mar 2020
33 citations
33 citations
1278 days before retraction
The role of RICTOR amplification in targeted therapy and drug resistance
Deze Zhao, Man Jiang, Xiaochun Zhang et al. (4 authors)
Molecular Medicine
Open Access
Published: Feb 2020
26 citations
26 citations
1306 days before retraction
Wnt/beta-catenin and PI3K/Akt/mTOR Signaling Pathways in Glioblastoma: Two Main Targets for Drug Design: A Review
Seyed Hossein Shahcheraghi, Venant Tchokonte-Nana, Marzieh Lotfi et al. (6 authors)
Current Pharmaceutical Design
Published: Jan 2020
104 citations
104 citations
1316 days before retraction
Repurposing Potential of Riluzole as an ITAF Inhibitor in mTOR Therapy Resistant Glioblastoma
Angelica Benavides-Serrato, Jacquelyn T. Saunders, Brent Holmes et al. (6 authors)
International Journal of Molecular Sciences
Open Access
Published: Jan 2020
25 citations
25 citations
1342 days before retraction
KPT-9274, an Inhibitor of PAK4 and NAMPT, Leads to Downregulation of mTORC2 in Triple Negative Breast Cancer Cells
Emma Cordover, Janet Wei, Chadni Patel et al. (11 authors)
Chemical Research in Toxicology
Open Access
Published: Dec 2019
35 citations
35 citations
1352 days before retraction
Targeting mTOR and Metabolism in Cancer: Lessons and Innovations
Cedric Magaway, Eugene Kim, Estela Jacinto
Cells
Open Access
Published: Dec 2019
201 citations
201 citations
1372 days before retraction
Sin1-mediated mTOR signaling in cell growth, metabolism and immune response
Chun Ruan, Xinxing Ouyang, Hongzhi Liu et al. (8 authors)
National Science Review
Open Access
Published: Nov 2019
18 citations
18 citations
1407 days before retraction
Ras functional proximity proteomics establishes mTORC2 as new direct ras effector
Joanna Kovalski, Ronald L. Shanderson, Paul A. Khavari
Oncotarget
Open Access
Published: Aug 2019
10 citations
10 citations
1473 days before retraction
Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition
Kara M. Ruicci, Paul Plantinga, Nicole Pinto et al. (13 authors)
Molecular Oncology
Open Access
Published: Aug 2019
29 citations
29 citations
1492 days before retraction
A Novel Therapeutic Induces DEPTOR Degradation in Multiple Myeloma Cells with Resulting Tumor Cytotoxicity
Mario I. Vega, Yijiang Shi, Patrick Frost et al. (10 authors)
Molecular Cancer Therapeutics
Open Access
Published: Aug 2019
11 citations
11 citations
1492 days before retraction
Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A – C-Raf
Connor M. Blair, Nicola M. Walsh, Bruce H. Littman et al. (5 authors)
BMC Cancer
Open Access
Published: Mar 2019
16 citations
16 citations
1628 days before retraction
Targeting the mTORC2 signaling complex in B cell malignancies
Wei Liao, Gwen Jordaan, Angelica Benavides-Serrato et al. (6 authors)
bioRxiv (Cold Spring Harbor Laboratory)
Open Access
Published: Mar 2019
1 citation
1 citation
1648 days before retraction
Correction: Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma
Angelica Benavides-Serrato, Jihye Lee, Brent Holmes et al. (8 authors)
PLoS ONE
Open Access
Published: Feb 2019
10 citations
10 citations
1675 days before retraction
The Functional Proximal Proteome of Oncogenic Ras Includes mTORC2
Joanna Kovalski, Aparna Bhaduri, Ashley Zehnder et al. (7 authors)
Molecular Cell
Open Access
Published: Jan 2019
130 citations
130 citations
1702 days before retraction
mTORC Inhibitors as Broad-Spectrum Therapeutics for Age-Related Diseases
Hannah Walters, Lynne S. Cox
International Journal of Molecular Sciences
Open Access
Published: Aug 2018
74 citations
74 citations
1857 days before retraction
Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex
Αναστάσιος Γκουντάκος, Sara Pilotto, Andrea Mafficini et al. (10 authors)
Carcinogenesis
Open Access
Published: Jun 2018
55 citations
55 citations
1900 days before retraction
Inflammation-induced mTORC2-Akt-mTORC1 signaling promotes macrophage foam cell formation
Dipanjan Banerjee, Archana Sinha, Sudeshna Saikia et al. (9 authors)
Biochimie
Published: Jun 2018
24 citations
24 citations
1920 days before retraction
mTORC Inhibitors as Broad-Spectrum Therapeutics for Age-Related Diseases
Hannah Walters, Lynne S. Cox
Unknown Journal
Open Access
Published: Jun 2018
26 citations
26 citations
1921 days before retraction
Inhibitors of protein–protein interactions (PPIs): an analysis of scaffold choices and buried surface area
Ran Xu, Jason E. Gestwicki
Current Opinion in Chemical Biology
Open Access
Published: Jun 2018
236 citations
236 citations
1925 days before retraction
Who does TORC2 talk to?
Jianling Xie, Xuemin Wang, Christopher G. Proud
Biochemical Journal
Published: May 2018
32 citations
32 citations
1933 days before retraction
The role of RICTOR downstream of receptor tyrosine kinase in cancers
Ahlem Jebali, Nicolas Dumaz
Molecular Cancer
Open Access
Published: Feb 2018
60 citations
60 citations
2031 days before retraction
Nutrient Sensing, Signaling and Ageing: The Role of IGF-1 and mTOR in Ageing and Age-Related Disease
Simon C. Johnson
Sub-cellular biochemistry/Subcellular biochemistry
Published: Jan 2018
78 citations
78 citations
2076 days before retraction
Towards specific inhibition of mTORC2
Elizabeth R. Murray, Angus J.M. Cameron
Aging
Open Access
Published: Dec 2017
16 citations
16 citations
2096 days before retraction
mTOR signaling in immune cells and its implications for cancer immunotherapy
Hu Zeng
Cancer Letters
Published: Sep 2017
43 citations
43 citations
2193 days before retraction
Related Records
This article has multiple records in the database due to different notices:
Record #58803
Feb 06, 2019Quick Stats
Total Citations:
79
Years Since Retraction:
2.2 years
Open Access:
Yes
Last Checked:
Jul 24, 2025